Can I Take St. John's Wort with Osphena (Ospemifene)?

What the Interaction Actually Is, and Why It Matters

St. John's Wort and ospemifene should not be taken together. The reason is straightforward: St. John's Wort revs up the liver enzyme system that breaks ospemifene down, so the drug is cleared from your blood before it can do its job. The result is reduced or absent relief from genitourinary syndrome of menopause (GSM).

This is not a minor pharmacokinetic footnote. GSM affects an estimated 27 to 84 percent of postmenopausal women depending on how it is measured, and painful intercourse is among the most distressing symptoms. Ospemifene is one of only a handful of oral, non-hormonal options approved specifically for that symptom. Losing its effectiveness through a supplement interaction is a real clinical loss.

What ospemifene does

Ospemifene is a selective estrogen receptor modulator (SERM). The FDA approved ospemifene 60 mg daily in 2013 for moderate-to-severe dyspareunia (painful sex) due to vulvovaginal atrophy from menopause, and later extended the indication to cover dryness. It acts as an estrogen agonist in vaginal tissue, thickening the epithelium and improving lubrication, without acting like estrogen in the uterus or breast at therapeutic doses.

Why the liver matters

Ospemifene is metabolized primarily by CYP3A4, with secondary contributions from CYP2C9 and CYP2C19. Any drug or supplement that turns those enzymes up will reduce how much ospemifene reaches your tissues.

How St. John's Wort Triggers the Interaction

St. John's Wort (Hypericum perforatum) activates pregnane X receptor (PXR), a nuclear receptor that acts as a master switch for drug-metabolizing enzymes. PXR activation drives transcription of CYP3A4 and the drug-efflux pump P-glycoprotein across the gut wall and liver. The result is faster first-pass metabolism and faster systemic clearance of any CYP3A4-sensitive substrate.

This mechanism is not unique to ospemifene. It is the same pathway responsible for documented reductions in plasma concentrations of cyclosporine, indinavir, warfarin, digoxin, and combined oral contraceptives when St. John's Wort is co-administered. The interaction with oral contraceptives is why many guidelines specifically warn against combining St. John's Wort with hormonal birth control, and the same enzyme logic applies to ospemifene.

How large is the drop in ospemifene levels?

Direct human pharmacokinetic data for ospemifene plus St. John's Wort specifically is limited. The ospemifene prescribing information flags strong CYP3A4 inducers as a drug class to avoid, without a dedicated study quantifying the precise magnitude of the ospemifene-SJW interaction. This is a genuine evidence gap: the interaction is inferred from ospemifene's metabolic profile and from SJW's well-characterized induction potency, not from a named ospemifene-specific trial.

What we do know: St. John's Wort reduced midazolam AUC by approximately 75 percent in a controlled pharmacokinetic study, midazolam being the archetypal CYP3A4 substrate. For drugs that are moderate to sensitive CYP3A4 substrates, reductions in the range of 40 to 70 percent are commonly reported. Ospemifene's metabolic sensitivity places it in a range where clinically meaningful loss of exposure is expected.

P-glycoprotein also plays a role

Beyond CYP3A4, St. John's Wort upregulates intestinal P-glycoprotein (Pgp), which pumps drug molecules back into the gut lumen before they are absorbed. For ospemifene, this means the interaction operates at two levels: reduced absorption through Pgp efflux, and faster hepatic clearance through CYP3A4. Both push in the same direction, toward lower drug levels.

The GSM Context: Why This Interaction Hits Women Especially Hard

GSM is a condition of postmenopause. It does not resolve on its own, and unlike hot flashes, it typically worsens over time without treatment. The Menopause Society (formerly NAMS) 2023 position statement on GSM notes that symptoms affect quality of life, sexual function, and urinary health, and that effective treatment is underused partly because women are not told it exists.

Ospemifene sits in a small category of oral options for women who cannot or prefer not to use vaginal estrogen. Women on tamoxifen for breast cancer, women with certain clotting histories, and women who find vaginal applicators impractical all may turn to ospemifene specifically. Losing its efficacy through an avoidable supplement interaction is a concrete harm.

Why perimenopausal women also need to know this

Ospemifene is indicated for postmenopausal women, but GSM can begin during perimenopause as estrogen levels fluctuate. Perimenopausal women in their 40s may also be managing mood changes, and St. John's Wort is disproportionately marketed to women for mild depression and PMS. The overlap between "trying natural remedies for mood" and "managing early GSM" is real. If you are perimenopausal and starting to notice vaginal dryness or pain, and also considering St. John's Wort for low mood, this interaction is directly relevant to you.

Other Interactions You Should Know About

St. John's Wort is not the only CYP3A4 concern with ospemifene.

The ospemifene label identifies several interaction categories that affect women across different clinical situations:

• Strong CYP3A4 inhibitors (fluconazole, ketoconazole, some HIV antiretrovirals): these increase ospemifene exposure, raising the risk of estrogenic side effects including endometrial stimulation. Fluconazole is extremely common in women being treated for recurrent vaginal yeast infections, making this particularly relevant.
• Fluconazole specifically: co-administration increased ospemifene AUC by approximately 2.7-fold in a dedicated pharmacokinetic study. That is a named trial result that appears in the prescribing label.
• Rifampin (a strong CYP3A4 inducer like SJW): reduced ospemifene AUC by approximately 58 percent in pharmacokinetic testing. This gives the clearest numerical anchor for what a strong inducer does to ospemifene levels, and supports the concern about SJW producing a similar or comparable reduction.
• CYP2C9 inhibitors: ospemifene is also metabolized by CYP2C9, so inhibitors of that enzyme (fluconazole, amiodarone, certain NSAIDs at high doses) compound the fluconazole interaction noted above.

Pregnancy and Lactation: What Every Woman Needs to Know

Ospemifene is contraindicated in pregnancy. This is not a cautionary note. It is a hard contraindication.

Ospemifene caused fetal harm in animal studies, including fetal loss and reduced fetal weight at doses below the human clinical dose. Human data in pregnancy do not exist because the drug should never be used in a pregnant woman. The drug's approved indication is specifically postmenopausal women, and it has no role in pregnancy at any stage.

What if I am still in perimenopause and have not confirmed menopause?

This matters clinically. Ospemifene is for postmenopausal women, meaning 12 consecutive months without a period (in the absence of other causes). If you are perimenopausal and still cycling, even irregularly, you may still ovulate and could still conceive. Ospemifene must not be used if there is any possibility of pregnancy. A sensitive urine or serum pregnancy test and confirmation of postmenopausal status should precede initiation.

Lactation

There are no human data on ospemifene transfer into breast milk. Animal data show it is present in rat milk. Given that ospemifene is a SERM with estrogenic activity, its potential to affect a nursing infant's hormonal milieu is a real concern even at low transfer rates. The prescribing information advises against use in nursing women. The Breastfeeding Network and LactMed do not list sufficient human data to establish safety.

St. John's Wort in pregnancy and lactation

This is equally important. Case reports and small studies document infant sedation, colic, and lethargy in breastfed infants whose mothers used St. John's Wort. Perinatal use has been associated with adverse neonatal outcomes in observational data. The European Medicines Agency advises against St. John's Wort use in pregnancy and breastfeeding. Both substances carry risks that make the combination particularly inappropriate outside of the postmenopausal context where ospemifene is approved.

What to Do If You Are Already Taking Both

Stop the St. John's Wort and contact your prescriber. Do not stop the ospemifene without discussing it first, because GSM symptoms can return quickly. Here is a practical sequence:

1. Discontinue St. John's Wort. CYP3A4 induction from St. John's Wort typically takes 1 to 2 weeks to resolve after stopping, because enzyme induction reverses as the inducing constituents (hyperforin) are cleared and induced enzyme protein degrades.
2. Expect a lag period of roughly 7 to 14 days before ospemifene plasma levels normalize.
3. Tell your clinician you were taking both. They may want to assess whether your GSM symptoms are adequately controlled.
4. Discuss what you were using St. John's Wort for. Mild depression, perimenopausal mood changes, and PMS all have evidence-based alternatives that do not interact with ospemifene.

The WomanRx CYP3A4 Supplement Check for Ospemifene Users

Before adding any supplement to ospemifene, run it through these three questions with your clinician:

• Does this supplement activate CYP3A4 or Pgp? (Red flag list includes St. John's Wort, high-dose echinacea, black cohosh at very high doses.)
• Does this supplement inhibit CYP3A4? (Red flag list includes grapefruit, pomelo, high-dose curcumin/turmeric, berberine.)
• Does this supplement have estrogenic activity that could add to or oppose ospemifene's SERM effects? (Examples include phytoestrogen-rich products: high-dose soy isoflavones, red clover.)

This three-question framework does not replace a pharmacist or prescriber review, but it gives you a starting vocabulary for the conversation.

Mood Support Alternatives That Do Not Interact with Ospemifene

Many women turn to St. John's Wort for mild depression or perimenopausal mood shifts. There are options that do not carry the CYP3A4 induction risk:

SSRIs and SNRIs

Several SSRIs and SNRIs have evidence for hot flash and mood management in menopause, including escitalopram, paroxetine (as the FDA-approved low-dose Brisdelle for vasomotor symptoms), and venlafaxine. Paroxetine is a potent CYP2D6 inhibitor, but ospemifene is not primarily metabolized by CYP2D6, making the interaction risk lower than with a CYP3A4-inducing supplement. Always confirm with your prescriber, because individual metabolic variation matters.

Cognitive behavioral therapy for insomnia and menopause (CBT-M)

CBT adapted for menopause has shown benefit for mood, insomnia, and quality of life in randomized trials, with no drug interaction risk whatsoever. It is underused partly because it requires effort, but the evidence is real.

Addressing the underlying hormone picture

Mood disturbance in perimenopause and early postmenopause often tracks estrogen fluctuation. For women who are not contraindicated for menopausal hormone therapy (MHT), adding low-dose estrogen has trial-level evidence for mood benefit in the perimenopause window. The NAMS 2022 Hormone Therapy Position Statement supports individualized MHT consideration. Combined MHT would need separate interaction review with ospemifene (a SERM plus estrogen is unusual clinically), but it illustrates that the mood concern has solutions that do not require St. John's Wort.

Who Ospemifene Is and Is Not Right For, by Life Stage

Postmenopausal women (the approved population)

Ospemifene 60 mg once daily with food is the standard indication. Women with a uterus should be aware that ospemifene carries a small endometrial stimulation signal in longer-term use, though the pooled trial data from the phase 3 studies did not show an increased rate of endometrial hyperplasia at 52 weeks compared to placebo. Annual endometrial surveillance is not routinely required but is clinically prudent in women with abnormal uterine bleeding.

Women with breast cancer history

Ospemifene's safety in women with a personal history of breast cancer has not been established in adequate trials. The ACOG and The Menopause Society both recommend caution and individualized discussion in this population. Women on tamoxifen (also a SERM) should not combine tamoxifen and ospemifene.

Women with PCOS

PCOS is primarily a condition of reproductive years, and ospemifene is not indicated during those years. Women with a history of PCOS who have entered postmenopause may use ospemifene if otherwise indicated; the prior PCOS diagnosis does not specifically contraindicate it, though cardiometabolic monitoring remains relevant in this group.

Perimenopausal women

Not currently indicated. Ospemifene is approved for postmenopausal women only. If you are perimenopausal with GSM symptoms starting, discuss options with your clinician, including vaginal estrogen, vaginal DHEA (prasterone), or non-hormonal vaginal moisturizers while you await confirmed menopause if that is the plan.

Women on anticoagulants

Ospemifene, as a SERM, carries a thromboembolic risk. The FDA label carries a boxed warning for stroke and deep vein thrombosis, derived from the SERM class label rather than a specific ospemifene DVT signal in trials, but the warning is there. Women on warfarin also need to know that St. John's Wort reduces warfarin efficacy through CYP2C9 induction, adding another layer of risk to SJW use in this group.

A Note on Evidence Gaps in Women's Pharmacology

The pharmacokinetic studies that established ospemifene's metabolic pathway were conducted in populations that reflect postmenopausal women reasonably well, because that is the intended population. The SJW-ospemifene interaction, however, is inferred rather than directly measured in a prospective human trial. No such trial appears to exist in the published literature as of this writing. This is a gap, not a reason for complacency. The mechanistic basis for the interaction is strong, the rifampin pharmacokinetic data provides a numerical analog, and the clinical recommendation to avoid the combination is well-grounded even without an ospemifene-SJW-specific study.

Women have historically been underrepresented in pharmacokinetic research, including supplement-drug interaction studies. The result is that a postmenopausal woman taking ospemifene for a condition that only women get is relying partly on extrapolation for CYP3A4-inducer interactions. Honest disclosure of this gap is part of giving you the information you need to make good decisions with your clinician.